Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Astrocytoma — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
Neuroepithelial Neoplasm
Glioma
Astrocytic Tumor
Astrocytoma

Subtype

Astrocytoma

CI-CAN-00004510Explore in graph →

Non-malignant74 active trials1 approved drugs24 evidence items

NCIt: C60781
OncoTree: ASTR
UMLS CUI: C0004114

Overview
Statistics
Survival
Genomics1
Variants & evidence24
Drugs8
Trials362
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (18)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–18 of 18 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

IDH1 and IDH2 mutations in gliomas.
· N Engl J Med · 2009 · PMID 19228619 · validated civic_curation pubmed
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
· Nat Genet · 2013 · PMID 23817572 · validated civic_curation pubmed
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.
· Cancer Res · 2008 · PMID 18974108 · validated civic_curation pubmed
A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration.
· Acta Neuropathol · 2019 · PMID 31595312 · validated civic_curation pubmed
Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.
· Acta Neuropathol · 2020 · PMID 31563982 · validated civic_curation pubmed
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.
· Proc Natl Acad Sci U S A · 2013 · PMID 23633565 · validated civic_curation pubmed
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
· Neuro Oncol · 2022 · PMID 35395680 · validated civic_curation

Showing 1–18 of 18 publications

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

· Neurology · 2009 · PMID 19933982 · validated civic_curation pubmed

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.

· Acta Neuropathol · 2013 · PMID 23904111 · validated civic_curation pubmed

Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.

· Nat Genet · 2014 · PMID 24705250 · validated civic_curation pubmed

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.

· Oncotarget · 2012 · PMID 23104868 · validated civic_curation pubmed

Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.

· Acta Neuropathol · 2016 · PMID 26810070 · validated civic_curation pubmed

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.

· J Transl Med · 2014 · PMID 25524464 · validated civic_curation pubmed

Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation.

· JCO Precis Oncol · 2022 · PMID 35507888 · validated civic_curation pubmed

CDKN2A/B Loss Is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma.

· Neuropathol Appl Neurobiol · 2019 · PMID 29804288 · validated civic_curation pubmed

MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas.

· Acta Neuropathol · 2010 · PMID 21046410 · validated civic_curation pubmed

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.

· Oncotarget · 2017 · PMID 28002790 · validated civic_curation pubmed

Tyrosine receptor kinase B is a drug target in astrocytomas.

· Neuro Oncol · 2017 · PMID 27402815 · validated civic_curation pubmed